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 CURRENTOPINION microRNAs in asthma: potential therapeutic targets
Catherine M. Greene and Kevin P. Gaughan
Purpose of review
Asthma is a global disease affecting millions of people. Current treatments are largely symptomatic and,
although often effective, can be associated with various side effects. microRNAs (miRNAs/miRs) are
regulatory RNAs that affect protein synthesis. They represent new therapeutic targets, and medicines that
target specific miRNAs may have potential in the treatment of asthma.
Recent findings
There have been a number of studies in the field of miRNA that implicate specific miRNAs in the
pathophysiology of asthma. For example, studies using mouse models have identified miRNAs that are
altered in response to allergen challenge. Certain miRNAs that are involved in the regulation of interleukin-
13 and the TH2 response, key components of the asthmatic response, have been shown to be amenable to
modulation by premiRs and antimiRs. Other studies have identified miRNAs that are implicated in bronchial
smooth muscle hyperresponsiveness and proliferation. Single-nucleotide polymorphisms in miRNA
responsive elements within asthma susceptibility genes, and also in miRNAs themselves, can also contribute
to the asthma phenotype.
Summary
Developing miRNA-based medicines to treat the pulmonary manifestations of asthma could yield
therapeutics with new properties that have the potential to treat both the inflammation and
hyperresponsivesness associated with this disease.
Keywords
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INTRODUCTION
Asthma is the reaction to inhaled antigens such as
respiratory viruses, allergens, or air pollutants that
results in airway inflammation, exaggerated airway
hyperresponsiveness (AHR), and reversible airflow
obstruction. Asthma afflicts both developed and
developing nations, and as of 2004, over 300million
people were affected worldwide [1]. In the United
States, 8.4% of the population have asthma, and it is
responsible for approximately 500000 hospitaliz-
ations and 1.9 million emergency room visits,
totaling $56 billion annually [2].
Current treatments are primarily glucocorti-
coids (e.g., dexamethasone) and inhaled short-
acting b-2 agonists, such as salbutanol. Although
these have yielded major improvements to patient
well being via their ability to inhibit multiple
inflammatory processes and prevent contraction
of the bronchial smooth muscles (BSMs), respect-
ively, they are associated with side effects ranging
from dysphonia and thrush to effects on the hypo-
thalamic–pituitary–adrenal system and cardiac
arrhythmia [3]. Some individuals are ‘glucocorticoid
resistant’. Thus, there is a clear need for new
therapeutics that can effectively treat asthma and
have fewer side effects.
microRNAs (miRNAs/miRs) are small noncoding
RNAs that regulate protein synthesis by way of
RNA silencing. miRNAs have been shown to have
a key role in cancer [4,5], viral infections [6], and
in pulmonary inflammatory diseases [7], such as
cystic fibrosis [8]. Herein, we outline the current
knowledge of miRNA function in asthma and how
miRs could be targets for future therapeutics.
ASTHMA
Individuals with asthma experience respiratory stress
that results frombronchial inflammation and smooth
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muscle contraction. Symptoms include reversible
airflow obstruction, AHR/bronchospasms, mucus
hypersecretion, and a poor forced expiratory volume1
percentage predicted. Multiple cellular changes
occur – themost significant being airway remodeling,
characterized by smooth muscle hyperplasia, sub-
epithelial cell fibrosis, goblet cell hyperplasia, and
neovascularization. Pulmonary inflammation is also
a major component of asthma involving influx of
mast cells, neutrophils, TH2 cells, and most notably
eosinophils. There is also a change in the smooth
muscle response wherein BSM cells become hyper-
responsive to acetylcholine stimulation.
The physiological changes that occur are due
to TH2-driven inflammation in response to allergen
exposure, resulting in increased TH2 cytokine
levels [interleukin (IL) 4, IL-5, IL-9, and IL-13] and
decreased anti-inflammatory cytokines (e.g., IL-10).
Together, these further promote the TH2 response
but also cause activation of natural killer cells, den-
dritic cells and eosinophils, promote eosinophila,
increase matrix metalloproteinase activity, increase
serum immunoglobulin E concentrations, and pro-
mote smooth muscle hypercontractiveness.
Both environmental exposure to air pollutants
and genetic predisposition can cause the heightened
TH2 response. Genes involved in inflammation [e.g.,
IL-10, STAT6, IL-4, IL-13, tumor necrosis factor
(TNF), IL-4R] or with a role in building immune
tolerance during fetal development (HLA-DRB1,
HLA-DQB1) have been implicated as genetic factors.
Given the importance of miRNAs in the regulation
of expression of up to 60% of the transcriptome,
it is worth considering their potential as new thera-
peutic targets for asthma.
MICRORNAS
miRNAs are small noncoding RNAs that regulate
protein synthesis by blocking translation or by
targeting mRNA transcripts for degradation. miRNA
regulation is complicated because a single mRNA
can be regulated by many miRNAs, and a single
miRNA can potentially regulate many mRNA tran-
scripts. miRs were first identified in Caenorhabitis
elegans, with the discovery of lin-4 [9].
Mature miRNAs are bound by the RNA-induced
silencing complex (RISC) in the cytosol to form
miRISC. This is guided to the appropriate mRNA
via the complementary binding between the 6–
8 nucleotide seed region, unique to each miRNA
and miRNA recognition elements (MRE) within the
3’untranslated region of the target mRNA. mRNA
translation is then prevented by blocking the ribo-
some reading the mRNA or by directing the mRNA
to p-bodies wherein the mRNA is degraded.
miRs represent a new class of drug target
and their therapeutic modulation is possible by
the use of over expression or antisense inhibition
approaches [10]. AntimiRNA oligonucleotides (anti-
miRs) anneal to miRNAs and inhibit their function.
Other antimiR methods include locked nucleic
acids [11] and cholesterol-conjugated so-called
‘antagomiRs’. miRNAs that are downregulated in
disease can be transiently replaced using double-
stranded miRNA mimetics called premiRs, or stably
using plasmids encoding primary, premiR or mature
miRNA. Plasmid or viral vectors expressing short-
hairpin RNAs can also be used to overexpress miRs
and have the potential for more persistent expres-
sion as this approach can facilitate the expression of
multiple miRs from one transcript [12]. Blocking
miRNA function in asthma via these approaches
may provide a new nonsteroidal anti-inflammatory
approach to treatment.
MICRORNA AND ASTHMA STUDIES
Although relatively few studies have been carried
out to date, there is evidence that miRs are impli-
cated in the asthmatic disease process (summarized
in Fig. 1). For example, profiling studies of lung
tissue from murine models of acute, intermediate,
and chronic asthma identified eight candidate miRs
likely to be implicated in asthma [13]. Data from
human miRNA profiling studies by Tsitsiou et al.
[14] identified selective downregulation of miR-28–
5p and miR-146a/b in CD8þ and CD4þ cells from
individuals with severe asthma that were associated
with widespread changes in mRNA expression.
microRNAs that affect cytokines and
inflammation
A selection of reports has described the role of
certain miRs in regulation of cytokine expression
and inflammation in asthma.
KEY POINTS
 Current asthma treatments are hampered by potentially
serious side effects and glucocorticoid resistance,
indicating a need for new therapeutics without these
associated problems.
 miRNAs have emerged as major cellular regulators, the
expression of which can be modulated by miR-based
medicines. Targeting miRNAs represents a new
therapeutic strategy for the treatment of asthma.
 Medicines based on over expressing let-7, miR-146, and
miR-133, or inhibiting expression of miR-126, miR-21,
miR-155, and miR-145 may be worthy if developed.
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miR-126
Using a mouse house dust mite (HDM) model of
asthma, Mattes et al. [15] identified changes in
miRNA expression in the airways. Three miRNAs
were significantly upregulated in the HDM model:
miR-16, miR-21, and miR-126. The increase in
miR-126 expression did not occur in Toll-like recep-
tor (TLR) 4/ and MyD88/ mice, suggesting that
lipopolysaccharide (LPS) activation is required for
the amplification of miR-126 levels. Knockout mice
experienced less AHR and less migration of immune
cells into the lungs in reaction to HDM, whereas
treatment of wild-type mice with antimiR-126
before HDM exposure resulted in less AHR and
mucus, and fewer eosinophils/neutrophils being
recruited. AntimiR-126 also decreased levels of
the TH2 cytokines IL-5 and IL-13. Subsequent anti-
miR-126 studies in an ovalbumin (OVA) model
showed a similar effect on the TH2 response [16].
Whether the effects were uniquely due to effects on
TH2 cytokines could not be determined, given that
eotaxin expression was also decreased in the airways
possibly as a consequence of lower TLR4 expression.
Let-7
The first attempt at identifying the role of the let-7
family in asthma showed that let-7 members,
specifically let-7a, had a proinflammatory role
[17]. Kumar et al. [18] disputed these findings by
reporting that increases in IL-13 in allergen-
challenged mice were unrelated to let-7a and later
went on to conduct work demonstrating that
members of the let-7 family are anti-inflammatory
and directly inhibit IL-13 expression [19
&
]. Intra-
nasal delivery of a let-7 mimic to lungs of mice with
allergic inflammation resulted in a decrease in IL-13
levels, resolution of airway inflammation, reduction
in AHR, and attenuation of mucus metaplasia
and subepithelial fibrosis. Thus, let-7 miRs inhibit
IL-13 expression and represent a major regulatory
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FIGURE 1. Overview of microRNA role in processes leading to asthma. Central to the progression of asthma is the cytokine
IL-13 and many microRNA directly or indirectly regulate its production. IL-13 is produced in response to TLR4 signaling that
is also regulated by microRNAs. Some of these serve as effectors of TLR4 activation, whereas others function as negative
feedback regulation. IgE, immunoglobulin E; IL, interleukin; SOCS, suppressor of cytokine signaling; TRAF6, TNF receptor-
associated factor 6; IRAK1, IL-1 receptor-associated kinase 1.
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mechanism for modulating IL-13 secretion in
IL-13-producing cell types, and thereby TH2 inflam-
mation. Therefore, let-7 would, thus, appear to
be anti-inflammatory, although an independent
repeat of these results would be needed to confirm
this conclusion.
miR-21
Lu et al. [20] provided the first significant insight
into the role of miR-21 in asthma by showing that
miR-21 expression could be stimulated by IL-13
and that miR-21 targets IL-12p35 mRNA and lowers
IL-12 protein expression. IL-12p35 plays a role in
balancing the TH2/TH1 skewing of T-helper cells;
less IL-12 expression would partially account for
the exaggerated TH2 response seen in asthma. This
work was expanded upon by studying the immune
response of miR-21/ mice [21]. Following OVA
stimulation, these mice produced greater interferon
(IFN) g and IL-12, whereas there was significantly
less IL-4 compared with normal OVA-treated
mice. Consequently, these mice had less influx of
eosinophils into the lung but experienced greater
TH1 hypersensitivity. Thus, Lu et al. have created
a valuable narrative of how IL-12 controls the TH1/
TH2 balance and how miRNA-21 in turn regulates
IL-12 and promotes TH2 skewing.
miR-21’s role in IL-12 regulation is not the
only proposed activity for this miR. Sheedy et al.
[22] have proposed that miR-21 can have an anti-
inflammatory/negative feedback regulatory role by
targeting PDCD4 [22]. PDCD4 is a proinflammatory
protein that downregulates IL-10 production. This
dual role for miR-21 demonstrates the complex
nature of miRNA regulation, and both studies make
the case for miR-21 being an immunomodulating
molecule.
miR-155
Another miRNA that could have a role in asthma
but has yet to be studied in an asthmamodel is miR-
155. miR-155 has a significant proinflammatory
role in response to LPS [23
&&
]. The anti-inflammatory
action of glucocorticoids has been shown to be
dependent on the downregulation of miR-155
activity, and miR-155 expression is nuclear factor
kappa B (NFkB)dependent. This would indicate that
miR-155 is a proinflammatory effector produced
in response to TLR4 signaling. Interestingly, miR-
155 promotes TH1 differentiation, as miR-155
/
mutants have enhanced TH2 cytokine production.
AlthoughmiR-155 has been studied in the context of
other disease states such as arthritis [24] and endo-
toxin shock, its well proven role in inflammation
warrants further study in the context of asthma,
particularly in how it pertains to TH2 differentiation.
miR-145
Although there is not extensive work done on a role
for miR-145 in asthma, Collison et al. [25] have
provided an insight into its proinflammatory role.
miR-145 is highly expressed in the airways, and its
expression is upregulated upon HDM stimulation
in mice [25]. Levels of miR-145 were decreased by
antimiR-145 administration in conjunction with
the HDM stimulation. Concomitant decreases in
goblet cells hyperplasia, peribronchial eosinophils,
and production of IL-5 and IL-13 were also evident.
The markedly anti-inflammatory effect of antimiR-
145 in this model was as striking as dexamethasone
treatment. Although no direct target ofmiR-145 was
demonstrated that could explain these effects,
miRNA-145 is likely to be a negative regulator
of the proinflammatory machinery, much like
miR-126 targeting of BOB.1/OBF.1.
miR-146
Similar to miR-155, miR-146 is an NFkB-dependent
miRNA that is transcribed upon LPS stimulation.
In contrast, however, miR-146 has been shown to
be a negative regulator of the TLR4 pathway,
participating as part of a negative feedback loop
to prevent an overexuberant response to LPS stimu-
lation.miR-146 is upregulated upon LPS stimulation
and based upon luciferase reporter assays it targets
TNF receptor-associated factor 6 (TRAF6) and IL-1
receptor-associated kinase 1 (IRAK1), both of which
are adaptor proteins involved in TLR signaling [26].
Indeed miR-146 mimics can decrease IL-6 and IL-8
expression by lowering IRAK1 and TRAF6 protein
expression [27], with earlier studies showing a
similar effect on regulated and normal T cell
expressed and secreted (RANTES) and IL-8 via IRAK1
regulation. In the past, miR-146 has also been
shown to inhibit cytokine-induced apoptosis in
human bronchial epithelial cells, suggesting that
it has an important role in asthma in terms of both
inflammation and airway remodeling.
Changes in miR-146a and miR-146b have been
reported‘in asthma. Feng et al. [28] observed that
miR-146a and miR-146b (and miRNA-181a) are
proinflammatory factors in asthma, and that down-
regulation of miRNA-146a may partially account for
the anti-inflammatory effect of dexamethasone.
How these findings tally with Tsitsiou et al. obser-
vations regarding reduced miR-146a in CD4þ and
CD8þT cells in vivo in patients with severe asthma
remains to be elucidated [14].
miR-106a
miR-106a is known to inhibit IL-10 in a post-
transcriptional manner. Recently, knockdown of
Asthma
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miR-106a in an established murine allergic airway
inflammation was shown to significantly alleviate
many features of asthma including AHR, airway
inflammation, increased Th2 response, goblet cell
metaplasia, and subepithelial fibrosis along with
increase in IL-10 levels in lung. The authors claim
that this work represents the first in-vivo proof
of a miRNA-mediated regulation of IL-10, with
a potential to reverse an established asthmatic
condition [29].
miR-221
It has been suggested thatmiR-221 plays a role in the
pathogenesis of asthma from studies showing that
its expression is increased in asthmatics. Further-
more, antagonism of miR-221 in a mouse OVA
model reduces airway inflammation [30]. Mayoral
et al., [31] having carried out mouse studies using
miR-221 lentiviral overexpression and depletion
system, suggest that it has mast cell-specific effects
and contributes to mast cell degranulation and
cytokine production.
microRNA that impact on bronchial smooth
muscle
A characteristic of the asthmatic lung is the altered
smoothmuscle response, whereby BSM cells become
hyperresponsive to acetylcholine stimulation.
Hyperresponsiveness and miR-133
The first suggestion that miR-133 could impact
asthma was from a study showing that miR-133
influenced cardiac muscle contraction and the
hypothesis that miR-133 could have a similar effect
on BSM [32]. This investigation elegantly demon-
strated that miR-133 could directly downregulate
RhoA protein expression, which is known to be a key
protein in hypercontractive smooth muscles seen in
asthma. It is also known that IL-13 can stimulate
an increase in RhoA protein and promote hyper-
contractiveness via STAT6. Chiba et al. [32] demon-
strated that IL-13 can decrease miR-133 expression
directly in a STAT6-independent mechanism. Thus,
in addition to its direct method of increasing
RhoA protein, IL-13 can indirectly increase RhoA
by lowering its regulator: miR-133 [33].
Phenotype and hypertrophy and miR-25
Although the hyperresponsiveness of smooth
muscle is an obvious concern, the proliferation
and change in phenotype of smooth muscle
cells also contribute to the heightened response to
stimulus and the production of inflammatory
mediators. Kuhn et al. [34] determined how an
inflammatory stimulus would affect miRNA expres-
sion and in turn how this change in miRNA levels
would affect the smooth muscle cell phenotype.
They first stimulated airway smooth muscle (ASM)
cells with a mixture of IL-1b, TNF-a, and IFN-g
and identified several lowered miRNAs including
miR-25. miRNA databases identified several genes
targeted by this miRNA including vitronectin recep-
tor integrin aV,myosin 1B,myocyte enhancer factor
2D, Kruppel-like factor 4 (KLF4), and suppressor of
cytokine signaling 5. Stimulated ASM cells given
antimiR-25 had a comparative decrease in many
cytokines including RANTES, IL-18, and eotaxin,
as well as myosin heavy chain (MYH11) that is
an essential protein in muscle contraction. Never-
theless, no predicted binding sites exist for miR-25
in the MYH11 transcript, and the explanation that
KLF4 is the mediator of these effects may be flawed
in that both miR-25 and KLF4 are decreased upon
cytokine stimulation. Therefore, although miR-25
could certainly be important in asthma, its role
requires further elucidation.
microRNA and genetics
HLA-G had been discovered to be an ‘asthma gene’,
that is, a gene in which single-nucleotide poly-
morphisms (SNPs) predispose an individual to
have asthma. HLA-G is produced by fetal cells at
the maternal–fetal boundary and helps to produce
maternal tolerance of the fetus by enhancing TH2
immunity. Maternal asthma is currently the greatest
risk factor for asthma in children, and HLA-G would
be a logical source of this predisposition as it is
highly expressed when and where the fetus is in
direct contact with the mother. In essence, it is
during this time that the fetus experiences its first
immune exposure. Tan et al. [35] focused on how
SNPs in HLA-G could impact on miRNA targeting.
They found that three miRNAs were predicted
to target HLA-G: miR-148a, miR-148b, and miR-
152. In the MRE for all of these miRNAs, there is a
SNP associated with asthma: þ3142C/G. Binding
of these miRNAs to the HLA-G mRNA occurs with
a G/G genotype, but with a C/C genotype, this
binding is less stable. Thus, a loss of miRNA regula-
tion because of an alteration of the MRE in the HLA-
G gene and an overexpression of HLA-G protein
could provide a mechanism for its association
with asthma. This is further supported by HLA-G
role in TH2 immunity as asthma is defined by a
TH2 response.
Su et al. [36
&
] conducted a study on SNPs in
miRNA sequences. Of the four SNPs studied (chosen
based on previous work), two appeared to be associ-
ated with a decreased risk of asthma: rs2910164G/C
microRNAs in asthma Greene and Gaughan
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and rs2292832C/T. What is interesting is that the
rs2910164 SNP exists in the premiRNA sequence
of miR-146, the negative regulator of the TLR4
pathway that targets TRAF6 and IRAK1. This SNP
is located in the stem loop of the premiR, potentially
leading to a change or loss of premiR-146 processing
or miR-146 function. Jimenez-Morales et al. [37]
recently provided evidence that rs2910164may play
a role in the susceptibility to childhood-onset
asthma by demonstrating a difference between
asthmatic and control women wherein the C allele
was significantly associated with protection to
asthma.
CONCLUSION
Although knowledge of the role of miRNAs in
asthma is still in its infancy, several miRNAs have
been identified that could promote or relegate the
progression of asthma. PremiR medicines based on
let-7 and miR-146 have the potential to correct the
overexuberant IL-13 and proinflammatory cytokine
expression, evident in the asthmatic lung, whereas
those based on miR-133 could potentially repair
the hyperresponsive defect in BSM cells. Conversely
by inhibiting expression of various miRs (miR-21,
miR-106a, miR-126, miR-145, miR-155, and miR-
221) using antimiR approaches, aberrant cytokine
expression and inflammation may be controlled.
As with all miR-based medicines, the efficacy and
specificity of the chosenmiRs/antimiRs, their ability
to be effectively delivered to the airways, and their
chronicity once they reach their intended location
are all aspects for development.
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